Prostate Cancer – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Prostate Cancer – Pipeline Review, H1 2017’, provides an overview of the Prostate Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Prostate Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Prostate Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Prostate Cancer

The report reviews pipeline therapeutics for Prostate Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Prostate Cancer therapeutics and enlists all their major and minor projects

The report assesses Prostate Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Prostate Cancer

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Prostate Cancer

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Prostate Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

3-V Biosciences Inc

4SC AG

AB Science SA

AbbVie Inc

Actinium Pharmaceuticals Inc

ADC Therapeutics Sarl

Addex Therapeutics Ltd

Aduro BioTech Inc

Advanced Accelerator Applications SA

Advanced Cancer Therapeutics LLC

Advantagene Inc

Advaxis Inc

Aeglea BioTherapeutics Inc

Aeolus Pharmaceuticals Inc

Aeterna Zentaris Inc

Akshaya Bio Inc

Alchemia Ltd

Alethia Biotherapeutics Inc

Alissa Pharma

Almac Discovery Ltd

Ambrx Inc

Amgen Inc

Anavex Life Sciences Corp

AndroScience Corp

AnGes MG Inc

AntiCancer Inc

Antigen Express Inc

Antisense Therapeutics Ltd

Apcure SAS

Aphios Corp

APIM Therapeutics AS

Aptevo Therapeutics Inc

Aptose Biosciences Inc

ARMO Biosciences Inc

Armour Therapeutics Inc

Arno Therapeutics Inc

ArQule Inc

Arrien Pharmaceuticals LLC

Arrowhead Pharmaceuticals Inc

Arvinas Inc

Asana BioSciences LLC

Asieris Pharmaceuticals Co Ltd

Astellas Pharma Inc

AstraZeneca Plc

Aurigene Discovery Technologies Ltd

Avipep Pty Ltd

Bavarian Nordic A/S

Bayer AG

BeiGene (Beijing) Co Ltd

Bexion Pharmaceuticals LLC

BHR Pharma LLC

Bio-Cancer Treatment International Ltd

Biotest AG

Biscayne Pharmaceuticals Inc

Blirt SA

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Bukwang Pharm Co Ltd

Camurus AB

Can-Fite BioPharma Ltd

CanBas Co Ltd

Cantex Pharmaceuticals Inc

CEL-SCI Corp

Celgene Corp

CellCentric Ltd

Celldex Therapeutics Inc

Cellectar Biosciences Inc

Cellmid Ltd

Cellular Biomedicine Group Inc

Celprogen Inc

Chamaeleo Pharma NV

Clovis Oncology Inc

CohBar Inc

Colby Pharmaceutical Company

Corcept Therapeutics Inc

Corvus Pharmaceuticals Inc

Crescendo Biologics Ltd

Curadis GmbH

CytomX Therapeutics Inc

Cytori Therapeutics Inc

CytoVac A/S

CZ BioMed Corp

Daewoong Co Ltd

Daewoong Pharmaceutical Co Ltd

Deciphera Pharmaceuticals LLC

DEKK-TEC Inc

DexTech Medical AB

Diffusion Pharmaceuticals Inc

DNJ Pharma Inc

Dongkook Pharmaceutical Co Ltd

Eisai Co Ltd

Eli Lilly and Company

Enceladus Pharmaceuticals BV

EndoCeutics Inc

Endocyte Inc

EntreChem SL

EOS Biosciences Inc

Errant Gene Therapeutics LLC

Esperance Pharmaceuticals Inc

ESSA Pharma Inc

Eureka Therapeutics Inc

Evgen Pharma Plc

Exonate Ltd

F. Hoffmann-La Roche Ltd

Ferring International Center SA

Foresee Pharmaceuticals LLC

Fountain Biopharma Inc

Fujifilm Corp

G1 Therapeutics Inc

Galectin Therapeutics Inc

Genelux Corp

Genentech Inc

GeneSegues Inc

Genmab A/S

Gilead Sciences Inc

Glactone Pharma AB

GlaxoSmithKline Plc

GlycoMimetics Inc

GP Pharm SA

GTx Inc

Hadasit Medical Research Services & Development Ltd

Hanmi Pharmaceuticals Co Ltd

Health Ever Bio-Tech Co Ltd

HitGen LTD

Hybrigenics SA

IC-MedTech Inc

Ideaya Biosciences Inc

IGF Oncology LLC

Ignyta Inc

Ildong Pharmaceutical Co Ltd

Immune Pharmaceuticals Inc

Immuneed AB

Immunocore Ltd

ImmunoFrontier Inc

Immunomedics Inc

Immupharma Plc

IMPACT Therapeutics Inc

Incanthera Ltd

Inflection Biosciences Ltd

InKemia IUCT Group SA

Innate Immunotherapeutics Ltd

Innovation Pharmaceuticals Inc

Inovio Pharmaceuticals Inc

Inspyr Therapeutics Inc

Intech Biopharm Ltd

Io Therapeutics Inc

Ionis Pharmaceuticals Inc

Jiangsu Hengrui Medicine Co Ltd

Johnson & Johnson

Jyant Technologies Inc

KaloBios Pharmaceuticals Inc

Karyopharm Therapeutics Inc

Kite Pharma Inc

Komipharm International Co Ltd

Konruns Pharmaceutical Co Ltd

Kura Oncology Inc

Kyowa Hakko Kirin Co Ltd

LATITUDE Pharmaceuticals Inc

Lidds AB

Luye Pharma Group Ltd

MacroGenics Inc

Mallinckrodt Plc

Mateon Therapeutics Inc

MaxiVAX SA

Meabco A/S

Med Discovery SA

MediaPharma Srl

MediGene AG

MedImmune LLC

Mediolanum farmaceutici SpA

MEI Pharma Inc

Merck & Co Inc

Merck KGaA

Merrimack Pharmaceuticals Inc

Microlin Bio Inc

Millennium Pharmaceuticals Inc

Minerva Biotechnologies Corp

Mirati Therapeutics Inc

Mithra Pharmaceuticals SA

MolMed SpA

Monopar Therapeutics LLC

Morphotek Inc

MTG Biotherapeutics Inc

NewLink Genetics Corp

NormOxys Inc

Novartis AG

Novogen Ltd

Novus Therapeutics Inc

Noxopharm Ltd

Nymox Pharmaceutical Corp

Oasmia Pharmaceutical AB

Omeros Corp

Omnitura Therapeutics Inc

OncBioMune Pharmaceuticals Inc

Oncodrone BV

Oncogenex Pharmaceuticals Inc

OncoMax

OncoNOx ApS

OncoTartis Inc

OncoTherapy Science Inc

Oncovir Inc

Oncternal Therapeutics Inc

Oneness Biotech Co Ltd

Ono Pharmaceutical Co Ltd

ORCA Therapeutics BV

Oribase Pharma

Oric Pharmaceuticals Inc

Orion Oyj

Orphagen Pharmaceuticals Inc

Oxford BioMedica Plc

Panacea Pharmaceuticals Inc

Patrys Ltd

PDS Biotechnology Corp

Peptron Inc

PepVax Inc

Pfizer Inc

Pharmedartis GmbH

Pharmicell Co Ltd

Pharminox Ltd

Philogen SpA

Polaris Pharmaceuticals Inc

Polyplus-Transfection SA

Prima BioMed Ltd

Progenics Pharmaceuticals Inc

Provectus Biopharmaceuticals Inc

Provenance Biopharmaceuticals Corp

PSites Pharma GmbH

Quintessence Biosciences Inc

Radiomedix Inc

RedHill Biopharma Ltd

Regulaxis SAS

RhoVac AB

Rubicon Biotechnology Inc

Sanofi

Selexel Sarl

Senhwa Biosciences Inc

Serometrix LLC

Shenogen Pharma Group Ltd

Shire Plc

Sierra Oncology Inc

Sophiris Bio Inc

Soricimed Biopharma Inc

Sorrento Therapeutics Inc

Sotio AS

Steba Biotech SA

Supratek Pharma Inc

SynDevRx Inc

SyntheX Inc

TaiGen Biotechnology Co Ltd

Taiho Pharmaceutical Co Ltd

Taiwan Liposome Company Ltd

Takeda Pharmaceutical Company Ltd

Takis Srl

Targovax ASA

Tarrex Biopharma Ltd

Terpenoid Therapeutics Inc

Tesaro Inc

Teva Pharmaceutical Industries Ltd

The Female Health Company

Theravectys SA

Threshold Pharmaceuticals Inc

Tolero Pharmaceuticals Inc

TRACON Pharmaceuticals Inc

TREAT U SA

Triphase Accelerator Corp

TVAX Biomedical Inc

Tyme Technologies Inc

UbiVac LLC

Ultimovacs AS

Vaccibody AS

ValiRx Plc

Vasgen Ltd

Vault Pharma Inc

Vaxeal Holding SA

Vaxon Biotech

Vicore Pharma AB

Vicus Therapeutics LLC

Viralytics Ltd

ViraTherapeutics GmbH

VLP Therapeutics LLC

Wilex AG

WntResearch AB

Xencor Inc

Yungjin Pharm Co Ltd

Zhejiang Hisun Pharmaceutical Co Ltd

Table of Contents

Table of Contents

Table of Contents 2

Introduction 13

Prostate Cancer - Overview 14

Prostate Cancer - Therapeutics Development 15

Prostate Cancer - Therapeutics Assessment 78

Prostate Cancer - Companies Involved in Therapeutics Development 113

Prostate Cancer - Drug Profiles 263

Prostate Cancer - Dormant Projects 1732

Prostate Cancer - Discontinued Products 1763

Prostate Cancer - Product Development Milestones 1774

Appendix 1784

List of Tables

List of Tables

Number of Products under Development for Prostate Cancer, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..7), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..8), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..9), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..10), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..11), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..12), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..13), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..14), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..15), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..16), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..17), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..18), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017 (Contd..3), H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Products under Development by Companies, H1 2017 (Contd..6), H1 2017

Products under Development by Companies, H1 2017 (Contd..7), H1 2017

Products under Development by Companies, H1 2017 (Contd..8), H1 2017

Products under Development by Companies, H1 2017 (Contd..9), H1 2017

Products under Development by Companies, H1 2017 (Contd..10), H1 2017

Products under Development by Companies, H1 2017 (Contd..11), H1 2017

Products under Development by Companies, H1 2017 (Contd..12), H1 2017

Products under Development by Companies, H1 2017 (Contd..13), H1 2017

Products under Development by Companies, H1 2017 (Contd..14), H1 2017

Products under Development by Companies, H1 2017 (Contd..15), H1 2017

Products under Development by Companies, H1 2017 (Contd..16), H1 2017

Products under Development by Companies, H1 2017 (Contd..17), H1 2017

Products under Development by Companies, H1 2017 (Contd..18), H1 2017

Products under Development by Companies, H1 2017 (Contd..19), H1 2017

Products under Development by Companies, H1 2017 (Contd..20), H1 2017

Products under Development by Companies, H1 2017 (Contd..21), H1 2017

Products under Development by Companies, H1 2017 (Contd..22), H1 2017

Products under Development by Companies, H1 2017 (Contd..23), H1 2017

Products under Development by Companies, H1 2017 (Contd..24), H1 2017

Products under Development by Companies, H1 2017 (Contd..25), H1 2017

Products under Development by Companies, H1 2017 (Contd..26), H1 2017

Products under Development by Companies, H1 2017 (Contd..27), H1 2017

Products under Development by Companies, H1 2017 (Contd..28), H1 2017

Products under Development by Universities/Institutes, H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..3), H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..4), H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..5), H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..5), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..6), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..7), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..8), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..9), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..10), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..11), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..12), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..13), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..6), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..7), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..8), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..9), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..10), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..11), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..12), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Number of Products by Stage and Molecule Type, H1 2017 (Contd..1), H1 2017

Prostate Cancer – Pipeline by 3-V Biosciences Inc, H1 2017

Prostate Cancer – Pipeline by 4SC AG, H1 2017

Prostate Cancer – Pipeline by AB Science SA, H1 2017

Prostate Cancer – Pipeline by AbbVie Inc, H1 2017

Prostate Cancer – Pipeline by Actinium Pharmaceuticals Inc, H1 2017

Prostate Cancer – Pipeline by ADC Therapeutics Sarl, H1 2017

Prostate Cancer – Pipeline by Addex Therapeutics Ltd, H1 2017

Prostate Cancer – Pipeline by Aduro BioTech Inc, H1 2017

Prostate Cancer – Pipeline by Advanced Accelerator Applications SA, H1 2017

Prostate Cancer – Pipeline by Advanced Cancer Therapeutics LLC, H1 2017

Prostate Cancer – Pipeline by Advantagene Inc, H1 2017

Prostate Cancer – Pipeline by Advaxis Inc, H1 2017

Prostate Cancer – Pipeline by Aeglea BioTherapeutics Inc, H1 2017

Prostate Cancer – Pipeline by Aeolus Pharmaceuticals Inc, H1 2017

Prostate Cancer – Pipeline by Aeterna Zentaris Inc, H1 2017

Prostate Cancer – Pipeline by Akshaya Bio Inc, H1 2017

Prostate Cancer – Pipeline by Alchemia Ltd, H1 2017

Prostate Cancer – Pipeline by Alethia Biotherapeutics Inc, H1 2017

Prostate Cancer – Pipeline by Alissa Pharma, H1 2017

Prostate Cancer – Pipeline by Almac Discovery Ltd, H1 2017

Prostate Cancer – Pipeline by Ambrx Inc, H1 2017

Prostate Cancer – Pipeline by Amgen Inc, H1 2017

Prostate Cancer – Pipeline by Anavex Life Sciences Corp, H1 2017

Prostate Cancer – Pipeline by AndroScience Corp, H1 2017

Prostate Cancer – Pipeline by AnGes MG Inc, H1 2017

Prostate Cancer – Pipeline by AntiCancer Inc, H1 2017

Prostate Cancer – Pipeline by Antigen Express Inc, H1 2017

Prostate Cancer – Pipeline by Antisense Therapeutics Ltd, H1 2017

Prostate Cancer – Pipeline by Apcure SAS, H1 2017

Prostate Cancer – Pipeline by Aphios Corp, H1 2017

Prostate Cancer – Pipeline by APIM Therapeutics AS, H1 2017

Prostate Cancer – Pipeline by Aptevo Therapeutics Inc, H1 2017

Prostate Cancer – Pipeline by Aptose Biosciences Inc, H1 2017

Prostate Cancer – Pipeline by ARMO Biosciences Inc, H1 2017

Prostate Cancer – Pipeline by Armour Therapeutics Inc, H1 2017

Prostate Cancer – Pipeline by Arno Therapeutics Inc, H1 2017

Prostate Cancer – Pipeline by ArQule Inc, H1 2017

Prostate Cancer – Pipeline by Arrien Pharmaceuticals LLC, H1 2017

Prostate Cancer – Pipeline by Arrowhead Pharmaceuticals Inc, H1 2017

Prostate Cancer – Pipeline by Arvinas Inc, H1 2017

Prostate Cancer – Pipeline by Asana BioSciences LLC, H1 2017

Prostate Cancer – Pipeline by Asieris Pharmaceuticals Co Ltd, H1 2017

Prostate Cancer – Pipeline by Astellas Pharma Inc, H1 2017

Prostate Cancer – Pipeline by AstraZeneca Plc, H1 2017

Prostate Cancer – Pipeline by Aurigene Discovery Technologies Ltd, H1 2017

Prostate Cancer – Pipeline by Avipep Pty Ltd, H1 2017

Prostate Cancer – Pipeline by Bavarian Nordic A/S, H1 2017

Prostate Cancer – Pipeline by Bayer AG, H1 2017

Prostate Cancer – Pipeline by BeiGene (Beijing) Co Ltd, H1 2017

Prostate Cancer – Pipeline by Bexion Pharmaceuticals LLC, H1 2017

Prostate Cancer – Pipeline by BHR Pharma LLC, H1 2017

Prostate Cancer – Pipeline by Bio-Cancer Treatment International Ltd, H1 2017

Prostate Cancer – Pipeline by Biotest AG, H1 2017

Prostate Cancer – Pipeline by Biscayne Pharmaceuticals Inc, H1 2017

Prostate Cancer – Pipeline by Blirt SA, H1 2017

Prostate Cancer – Pipeline by Boehringer Ingelheim GmbH, H1 2017

Prostate Cancer – Pipeline by Bristol-Myers Squibb Company, H1 2017

Prostate Cancer – Pipeline by Bukwang Pharm Co Ltd, H1 2017

Prostate Cancer – Pipeline by Camurus AB, H1 2017

Prostate Cancer – Pipeline by Can-Fite BioPharma Ltd, H1 2017

Prostate Cancer – Pipeline by CanBas Co Ltd, H1 2017

Prostate Cancer – Pipeline by Cantex Pharmaceuticals Inc, H1 2017

Prostate Cancer – Pipeline by CEL-SCI Corp, H1 2017

Prostate Cancer – Pipeline by Celgene Corp, H1 2017

Prostate Cancer – Pipeline by CellCentric Ltd, H1 2017

Prostate Cancer – Pipeline by Celldex Therapeutics Inc, H1 2017

Prostate Cancer – Pipeline by Cellectar Biosciences Inc, H1 2017

Prostate Cancer – Pipeline by Cellmid Ltd, H1 2017

Prostate Cancer – Pipeline by Cellular Biomedicine Group Inc, H1 2017

Prostate Cancer – Pipeline by Celprogen Inc, H1 2017

Prostate Cancer – Pipeline by Chamaeleo Pharma NV, H1 2017

Prostate Cancer – Pipeline by Clovis Oncology Inc, H1 2017

Prostate Cancer – Pipeline by CohBar Inc, H1 2017

Prostate Cancer – Pipeline by Colby Pharmaceutical Company, H1 2017

Prostate Cancer – Pipeline by Corcept Therapeutics Inc, H1 2017

Prostate Cancer – Pipeline by Corvus Pharmaceuticals Inc, H1 2017

Prostate Cancer – Pipeline by Crescendo Biologics Ltd, H1 2017

Prostate Cancer – Pipeline by Curadis GmbH, H1 2017

Prostate Cancer – Pipeline by CytomX Therapeutics Inc, H1 2017

Prostate Cancer – Pipeline by Cytori Therapeutics Inc, H1 2017

Prostate Cancer – Pipeline by CytoVac A/S, H1 2017

Prostate Cancer – Pipeline by CZ BioMed Corp, H1 2017

Prostate Cancer – Pipeline by Daewoong Co Ltd, H1 2017

Prostate Cancer – Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2017

Prostate Cancer – Pipeline by Deciphera Pharmaceuticals LLC, H1 2017

Prostate Cancer – Pipeline by DEKK-TEC Inc, H1 2017

Prostate Cancer – Pipeline by DexTech Medical AB, H1 2017

Prostate Cancer – Pipeline by Diffusion Pharmaceuticals Inc, H1 2017

Prostate Cancer – Pipeline by DNJ Pharma Inc, H1 2017

Prostate Cancer – Pipeline by Dongkook Pharmaceutical Co Ltd, H1 2017

Prostate Cancer – Pipeline by Eisai Co Ltd, H1 2017

Prostate Cancer – Pipeline by Eli Lilly and Company, H1 2017

Prostate Cancer – Pipeline by Enceladus Pharmaceuticals BV, H1 2017

Prostate Cancer – Pipeline by EndoCeutics Inc, H1 2017

Prostate Cancer – Pipeline by Endocyte Inc, H1 2017

Prostate Cancer – Pipeline by EntreChem SL, H1 2017

Prostate Cancer – Pipeline by EOS Biosciences Inc, H1 2017

Prostate Cancer – Pipeline by Errant Gene Therapeutics LLC, H1 2017

Prostate Cancer – Pipeline by Esperance Pharmaceuticals Inc, H1 2017

Prostate Cancer – Pipeline by ESSA Pharma Inc, H1 2017

Prostate Cancer – Pipeline by Eureka Therapeutics Inc, H1 2017

Prostate Cancer – Pipeline by Evgen Pharma Plc, H1 2017

Prostate Cancer – Pipeline by Exonate Ltd, H1 2017

Prostate Cancer – Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Prostate Cancer – Pipeline by Ferring International Center SA, H1 2017

Prostate Cancer – Pipeline by Foresee Pharmaceuticals LLC, H1 2017

Prostate Cancer – Pipeline by Fountain Biopharma Inc, H1 2017

Prostate Cancer – Pipeline by Fujifilm Corp, H1 2017

Prostate Cancer – Pipeline by G1 Therapeutics Inc, H1 2017

Prostate Cancer – Pipeline by Galectin Therapeutics Inc, H1 2017

Prostate Cancer – Pipeline by Genelux Corp, H1 2017

Prostate Cancer – Pipeline by Genentech Inc, H1 2017

Prostate Cancer – Pipeline by GeneSegues Inc, H1 2017

Prostate Cancer – Pipeline by Genmab A/S, H1 2017

Prostate Cancer – Pipeline by Gilead Sciences Inc, H1 2017

Prostate Cancer – Pipeline by Glactone Pharma AB, H1 2017

Prostate Cancer – Pipeline by GlaxoSmithKline Plc, H1 2017

Prostate Cancer – Pipeline by GlycoMimetics Inc, H1 2017

Prostate Cancer – Pipeline by GP Pharm SA, H1 2017

Prostate Cancer – Pipeline by GTx Inc, H1 2017

Prostate Cancer – Pipeline by Hadasit Medical Research Services & Development Ltd, H1 2017

Prostate Cancer – Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017

Prostate Cancer – Pipeline by Health Ever Bio-Tech Co Ltd, H1 2017

Prostate Cancer – Pipeline by HitGen LTD, H1 2017

Prostate Cancer – Pipeline by Hybrigenics SA, H1 2017

Prostate Cancer – Pipeline by IC-MedTech Inc, H1 2017

Prostate Cancer – Pipeline by Ideaya Biosciences Inc, H1 2017

Prostate Cancer – Pipeline by IGF Oncology LLC, H1 2017

Prostate Cancer – Pipeline by Ignyta Inc, H1 2017

Prostate Cancer – Pipeline by Ildong Pharmaceutical Co Ltd, H1 2017

Prostate Cancer – Pipeline by Immune Pharmaceuticals Inc, H1 2017

Prostate Cancer – Pipeline by Immuneed AB, H1 2017

Prostate Cancer – Pipeline by Immunocore Ltd, H1 2017

Prostate Cancer – Pipeline by ImmunoFrontier Inc, H1 2017

Prostate Cancer – Pipeline by Immunomedics Inc, H1 2017

Prostate Cancer – Pipeline by Immupharma Plc, H1 2017

Prostate Cancer – Pipeline by IMPACT Therapeutics Inc, H1 2017

Prostate Cancer – Pipeline by Incanthera Ltd, H1 2017

Prostate Cancer – Pipeline by Inflection Biosciences Ltd, H1 2017

Prostate Cancer – Pipeline by InKemia IUCT Group SA, H1 2017

Prostate Cancer – Pipeline by Innate Immunotherapeutics Ltd, H1 2017

Prostate Cancer – Pipeline by Innovation Pharmaceuticals Inc, H1 2017

Prostate Cancer – Pipeline by Inovio Pharmaceuticals Inc, H1 2017

Prostate Cancer – Pipeline by Inspyr Therapeutics Inc, H1 2017

Prostate Cancer – Pipeline by Intech Biopharm Ltd, H1 2017

Prostate Cancer – Pipeline by Io Therapeutics Inc, H1 2017

Prostate Cancer – Pipeline by Ionis Pharmaceuticals Inc, H1 2017

Prostate Cancer – Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017

Prostate Cancer – Pipeline by Johnson & Johnson, H1 2017

Prostate Cancer – Pipeline by Jyant Technologies Inc, H1 2017

Prostate Cancer – Pipeline by KaloBios Pharmaceuticals Inc, H1 2017

Prostate Cancer – Pipeline by Karyopharm Therapeutics Inc, H1 2017

Prostate Cancer – Pipeline by Kite Pharma Inc, H1 2017

Prostate Cancer – Pipeline by Komipharm International Co Ltd, H1 2017

Prostate Cancer – Pipeline by Konruns Pharmaceutical Co Ltd, H1 2017

Prostate Cancer – Pipeline by Kura Oncology Inc, H1 2017

Prostate Cancer – Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2017

Prostate Cancer – Pipeline by LATITUDE Pharmaceuticals Inc, H1 2017

Prostate Cancer – Pipeline by Lidds AB, H1 2017

Prostate Cancer – Pipeline by Luye Pharma Group Ltd, H1 2017

Prostate Cancer – Pipeline by MacroGenics Inc, H1 2017

Prostate Cancer – Pipeline by Mallinckrodt Plc, H1 2017

Prostate Cancer – Pipeline by Mateon Therapeutics Inc, H1 2017

Prostate Cancer – Pipeline by MaxiVAX SA, H1 2017

Prostate Cancer – Pipeline by Meabco A/S, H1 2017

Prostate Cancer – Pipeline by Med Discovery SA, H1 2017

Prostate Cancer – Pipeline by MediaPharma Srl, H1 2017

Prostate Cancer – Pipeline by MediGene AG, H1 2017

Prostate Cancer – Pipeline by MedImmune LLC, H1 2017

Prostate Cancer – Pipeline by Mediolanum farmaceutici SpA, H1 2017

Prostate Cancer – Pipeline by MEI Pharma Inc, H1 2017

Prostate Cancer – Pipeline by Merck & Co Inc, H1 2017

Prostate Cancer – Pipeline by Merck KGaA, H1 2017

Prostate Cancer – Pipeline by Merrimack Pharmaceuticals Inc, H1 2017

Prostate Cancer – Pipeline by Microlin Bio Inc, H1 2017

Prostate Cancer – Pipeline by Millennium Pharmaceuticals Inc, H1 2017

Prostate Cancer – Pipeline by Minerva Biotechnologies Corp, H1 2017

Prostate Cancer – Pipeline by Mirati Therapeutics Inc, H1 2017

Prostate Cancer – Pipeline by Mithra Pharmaceuticals SA, H1 2017

Prostate Cancer – Pipeline by MolMed SpA, H1 2017

Prostate Cancer – Pipeline by Monopar Therapeutics LLC, H1 2017

Prostate Cancer – Pipeline by Morphotek Inc, H1 2017

Prostate Cancer – Pipeline by MTG Biotherapeutics Inc, H1 2017

Prostate Cancer – Pipeline by NewLink Genetics Corp, H1 2017

Prostate Cancer – Pipeline by NormOxys Inc, H1 2017

Prostate Cancer – Pipeline by Novartis AG, H1 2017

Prostate Cancer – Pipeline by Novogen Ltd, H1 2017

Prostate Cancer – Pipeline by Novus Therapeutics Inc, H1 2017

Prostate Cancer – Pipeline by Noxopharm Ltd, H1 2017

Prostate Cancer – Pipeline by Nymox Pharmaceutical Corp, H1 2017

Prostate Cancer – Pipeline by Oasmia Pharmaceutical AB, H1 2017

Prostate Cancer – Pipeline by Omeros Corp, H1 2017

Prostate Cancer – Pipeline by Omnitura Therapeutics Inc, H1 2017

Prostate Cancer – Pipeline by OncBioMune Pharmaceuticals Inc, H1 2017

Prostate Cancer – Pipeline by Oncodrone BV, H1 2017

Prostate Cancer – Pipeline by Oncogenex Pharmaceuticals Inc, H1 2017

Prostate Cancer – Pipeline by OncoMax, H1 2017

Prostate Cancer – Pipeline by OncoNOx ApS, H1 2017

Prostate Cancer – Pipeline by OncoTartis Inc, H1 2017

Prostate Cancer – Pipeline by OncoTherapy Science Inc, H1 2017

Prostate Cancer – Pipeline by Oncovir Inc, H1 2017

Prostate Cancer – Pipeline by Oncternal Therapeutics Inc, H1 2017

Prostate Cancer – Pipeline by Oneness Biotech Co Ltd, H1 2017

Prostate Cancer – Pipeline by Ono Pharmaceutical Co Ltd, H1 2017

Prostate Cancer – Pipeline by ORCA Therapeutics BV, H1 2017

Prostate Cancer – Pipeline by Oribase Pharma, H1 2017

Prostate Cancer – Pipeline by Oric Pharmaceuticals Inc, H1 2017

Prostate Cancer – Pipeline by Orion Oyj, H1 2017

Prostate Cancer – Pipeline by Orphagen Pharmaceuticals Inc, H1 2017

Prostate Cancer – Pipeline by Oxford BioMedica Plc, H1 2017

Prostate Cancer – Pipeline by Panacea Pharmaceuticals Inc, H1 2017

Prostate Cancer – Pipeline by Patrys Ltd, H1 2017

Prostate Cancer – Pipeline by PDS Biotechnology Corp, H1 2017

Prostate Cancer – Pipeline by Peptron Inc, H1 2017

Prostate Cancer – Pipeline by PepVax Inc, H1 2017

Prostate Cancer – Pipeline by Pfizer Inc, H1 2017

Prostate Cancer – Pipeline by Pharmedartis GmbH, H1 2017

Prostate Cancer – Pipeline by Pharmicell Co Ltd, H1 2017

Prostate Cancer – Pipeline by Pharminox Ltd, H1 2017

Prostate Cancer – Pipeline by Philogen SpA, H1 2017

Prostate Cancer – Pipeline by Polaris Pharmaceuticals Inc, H1 2017

Prostate Cancer – Pipeline by Polyplus-Transfection SA, H1 2017

Prostate Cancer – Pipeline by Prima BioMed Ltd, H1 2017

Prostate Cancer – Pipeline by Progenics Pharmaceuticals Inc, H1 2017

Prostate Cancer – Pipeline by Provectus Biopharmaceuticals Inc, H1 2017

Prostate Cancer – Pipeline by Provenance Biopharmaceuticals Corp, H1 2017

Prostate Cancer – Pipeline by PSites Pharma GmbH, H1 2017

Prostate Cancer – Pipeline by Quintessence Biosciences Inc, H1 2017

Prostate Cancer – Pipeline by Radiomedix Inc, H1 2017

Prostate Cancer – Pipeline by RedHill Biopharma Ltd, H1 2017

Prostate Cancer – Pipeline by Regulaxis SAS, H1 2017

Prostate Cancer – Pipeline by RhoVac AB, H1 2017

Prostate Cancer – Pipeline by Rubicon Biotechnology Inc, H1 2017

Prostate Cancer – Pipeline by Sanofi, H1 2017

Prostate Cancer – Pipeline by Selexel Sarl, H1 2017

Prostate Cancer – Pipeline by Senhwa Biosciences Inc, H1 2017

Prostate Cancer – Pipeline by Serometrix LLC, H1 2017

Prostate Cancer – Pipeline by Shenogen Pharma Group Ltd, H1 2017

Prostate Cancer – Pipeline by Shire Plc, H1 2017

Prostate Cancer – Pipeline by Sierra Oncology Inc, H1 2017

Prostate Cancer – Pipeline by Sophiris Bio Inc, H1 2017

Prostate Cancer – Pipeline by Soricimed Biopharma Inc, H1 2017

Prostate Cancer – Pipeline by Sorrento Therapeutics Inc, H1 2017

Prostate Cancer – Pipeline by Sotio AS, H1 2017

Prostate Cancer – Pipeline by Steba Biotech SA, H1 2017

Prostate Cancer – Pipeline by Supratek Pharma Inc, H1 2017

Prostate Cancer – Pipeline by SynDevRx Inc, H1 2017

Prostate Cancer – Pipeline by SyntheX Inc, H1 2017

Prostate Cancer – Pipeline by TaiGen Biotechnology Co Ltd, H1 2017

Prostate Cancer – Pipeline by Taiho Pharmaceutical Co Ltd, H1 2017

Prostate Cancer – Pipeline by Taiwan Liposome Company Ltd, H1 2017

Prostate Cancer – Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017

Prostate Cancer – Pipeline by Takis Srl, H1 2017

Prostate Cancer – Pipeline by Targovax ASA, H1 2017

Prostate Cancer – Pipeline by Tarrex Biopharma Ltd, H1 2017

Prostate Cancer – Pipeline by Terpenoid Therapeutics Inc, H1 2017

Prostate Cancer – Pipeline by Tesaro Inc, H1 2017

Prostate Cancer – Pipeline by Teva Pharmaceutical Industries Ltd, H1 2017

Prostate Cancer – Pipeline by The Female Health Company, H1 2017

Prostate Cancer – Pipeline by Theravectys SA, H1 2017

Prostate Cancer – Pipeline by Threshold Pharmaceuticals Inc, H1 2017

Prostate Cancer – Pipeline by Tolero Pharmaceuticals Inc, H1 2017

Prostate Cancer – Pipeline by TRACON Pharmaceuticals Inc, H1 2017

Prostate Cancer – Pipeline by TREAT U SA, H1 2017

Prostate Cancer – Pipeline by Triphase Accelerator Corp, H1 2017

Prostate Cancer – Pipeline by TVAX Biomedical Inc, H1 2017

Prostate Cancer – Pipeline by Tyme Technologies Inc, H1 2017

Prostate Cancer – Pipeline by UbiVac LLC, H1 2017

Prostate Cancer – Pipeline by Ultimovacs AS, H1 2017

Prostate Cancer – Pipeline by Vaccibody AS, H1 2017

Prostate Cancer – Pipeline by ValiRx Plc, H1 2017

Prostate Cancer – Pipeline by Vasgen Ltd, H1 2017

Prostate Cancer – Pipeline by Vault Pharma Inc, H1 2017

Prostate Cancer – Pipeline by Vaxeal Holding SA, H1 2017

Prostate Cancer – Pipeline by Vaxon Biotech, H1 2017

Prostate Cancer – Pipeline by Vicore Pharma AB, H1 2017

Prostate Cancer – Pipeline by Vicus Therapeutics LLC, H1 2017

Prostate Cancer – Pipeline by Viralytics Ltd, H1 2017

Prostate Cancer – Pipeline by ViraTherapeutics GmbH, H1 2017

Prostate Cancer – Pipeline by VLP Therapeutics LLC, H1 2017

Prostate Cancer – Pipeline by Wilex AG, H1 2017

Prostate Cancer – Pipeline by WntResearch AB, H1 2017

Prostate Cancer – Pipeline by Xencor Inc, H1 2017

Prostate Cancer – Pipeline by Yungjin Pharm Co Ltd, H1 2017

Prostate Cancer – Pipeline by Zhejiang Hisun Pharmaceutical Co Ltd, H1 2017

Prostate Cancer – Dormant Projects, H1 2017

Prostate Cancer – Dormant Projects, H1 2017 (Contd..1), H1 2017

Prostate Cancer – Dormant Projects, H1 2017 (Contd..2), H1 2017

Prostate Cancer – Dormant Projects, H1 2017 (Contd..3), H1 2017

Prostate Cancer – Dormant Projects, H1 2017 (Contd..4), H1 2017

Prostate Cancer – Dormant Projects, H1 2017 (Contd..5), H1 2017

Prostate Cancer – Dormant Projects, H1 2017 (Contd..6), H1 2017

Prostate Cancer – Dormant Projects, H1 2017 (Contd..7), H1 2017

Prostate Cancer – Dormant Projects, H1 2017 (Contd..8), H1 2017

Prostate Cancer – Dormant Projects, H1 2017 (Contd..9), H1 2017

Prostate Cancer – Dormant Projects, H1 2017 (Contd..10), H1 2017

Prostate Cancer – Dormant Projects, H1 2017 (Contd..11), H1 2017

Prostate Cancer – Dormant Projects, H1 2017 (Contd..12), H1 2017

Prostate Cancer – Dormant Projects, H1 2017 (Contd..13), H1 2017

Prostate Cancer – Dormant Projects, H1 2017 (Contd..14), H1 2017

Prostate Cancer – Dormant Projects, H1 2017 (Contd..15), H1 2017

Prostate Cancer – Dormant Projects, H1 2017 (Contd..16), H1 2017

Prostate Cancer – Dormant Projects, H1 2017 (Contd..17), H1 2017

Prostate Cancer – Dormant Projects, H1 2017 (Contd..18), H1 2017

Prostate Cancer – Dormant Projects, H1 2017 (Contd..19), H1 2017

Prostate Cancer – Dormant Projects, H1 2017 (Contd..20), H1 2017

Prostate Cancer – Dormant Projects, H1 2017 (Contd..21), H1 2017

Prostate Cancer – Dormant Projects, H1 2017 (Contd..22), H1 2017

Prostate Cancer – Dormant Projects, H1 2017 (Contd..23), H1 2017

Prostate Cancer – Dormant Projects, H1 2017 (Contd..24), H1 2017

Prostate Cancer – Dormant Projects, H1 2017 (Contd..25), H1 2017

Prostate Cancer – Discontinued Products, H1 2017

Prostate Cancer – Discontinued Products, H1 2017 (Contd..1), H1 2017

Prostate Cancer – Discontinued Products, H1 2017 (Contd..2), H1 2017

Prostate Cancer – Discontinued Products, H1 2017 (Contd..3), H1 2017

Prostate Cancer – Discontinued Products, H1 2017 (Contd..4), H1 2017

Prostate Cancer – Discontinued Products, H1 2017 (Contd..5), H1 2017

List of Figures

List of Figures

Number of Products under Development for Prostate Cancer, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Top 10 Routes of Administration, H1 2017

Number of Products by Stage and Top 10 Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports